Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $32.01 USD
Change Today -0.25 / -0.77%
Volume 476.0K
ACOR On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

acorda therapeutics inc (ACOR) Key Developments

Acorda Therapeutics, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 03:40 PM

Acorda Therapeutics, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 03:40 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Michael W. Rogers, Chief Financial Officer.

Acorda Therapeutics, Inc. Presents at NewYork BIO 25th Anniversary Conference 2015, May-05-2015 03:00 PM

Acorda Therapeutics, Inc. Presents at NewYork BIO 25th Anniversary Conference 2015, May-05-2015 03:00 PM. Venue: Time Warner Center, New York, United States. Speakers: Jane Wasman, President of International, General Counsel and Corporate Secretary.

Acorda Therapeutics, Inc. Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2015; Reiterates Earnings Guidance for 2015

Acorda Therapeutics, Inc. announced unaudited consolidated financial results for the first quarter ended March 31, 2015. The company reported a GAAP net loss of $3.1 million for the quarter ended March 31, 2015, or $0.07 per diluted share. GAAP net income in the same quarter of 2014 was $0.7 million, or $0.02 per diluted share. Non-GAAP net income for the quarter ended March 31, 2015 was $6.5 million, or $0.15 per diluted share. Non-GAAP net income in the same quarter of 2014 was $8.8 million, or $0.21 per diluted share. For the quarter ended March 31, 2015, the company reported combined net revenue and royalties from ZANAFLEX and tizanidine of $2.6 million compared to $3.1 million for the same quarter in 2014. Total revenue was $99,851,000 compared to $80,518,000 a year ago. Operating loss was $1,259,000 compared to income of $3,416,000 a year ago. Loss before income taxes was $5,123,000 compared to income of $3,496,000 a year ago. The company is reiterating 2015 AMPYRA net sales guidance of $405-$420 million. The company is reiterating 2015 R&D guidance of $150-$160 million. The company is reiterating 2015 SG&A guidance of $180-$190 million. The company expects to be cash flow positive in 2015.

Acorda Therapeutics, Inc., Q1 2015 Earnings Call, Apr 30, 2015

Acorda Therapeutics, Inc., Q1 2015 Earnings Call, Apr 30, 2015

Acorda Therapeutics, Inc. Presents Data on First Clinical Study of Remyelinating Antibody for Multiple Sclerosis at American Academy of Neurology Annual Meeting

Acorda Therapeutics, Inc. presented data from a Phase 1 clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis (MS). Safety data showed rHIgM22 was well-tolerated in each of the five tested doses, supporting additional clinical development. In addition, testing detected rHIgM22 in cerebrospinal fluid (CSF), indicating the drug’s access to the central nervous system. These data were presented at the 67th American Academy of Neurology Annual Meeting in Washington, DC. This was a placebo-controlled, single-dose, escalating study in 72 patients with clinically stable MS to explore dose tolerability for six months after treatment. rHIgM22 was well-tolerated at all doses tested, with no safety signals identified. There were no dose-limiting toxicities and no serious adverse events in any of the five rHIgM22 dose levels in the study. The data presented included the concentration of rHIgM22 in the CSF at two days and four weeks after IV infusion. The antibody was measured at levels expected for antibodies of this class. There were no significant changes from baseline in clinical measures including MRI, magnetic resonance spectroscopy, Expanded Disability Status Scale, Timed 25-Foot Walk, and low contrast visual acuity. The most commonly observed adverse events (>5% in the combined rHIgM22 treatment groups) reported in the study were: headache, contact dermatitis, multiple sclerosis relapse, infusion site hematoma, fatigue, arthralgia, back pain, muscular weakness, neck pain, pain in an extremity, pruritus, contusion, and flushing. No participants withdrew due to adverse events. No safety signals were identified by standard clinical MRI evaluations, or standard clinical, laboratory or ECG assessments. The data were presented in a poster, “Safety and Tolerability of the Remyelinating Therapeutic Antibody rHIgM22 in Patients with Stable Multiple Sclerosis” (poster presentation number P4.339). Top-line safety and tolerability data were previously announced by the Company in February 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACOR:US $32.01 USD -0.25

ACOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ACADIA Pharmaceuticals Inc $40.55 USD +0.33
Biogen Inc $398.68 USD -2.47
Depomed Inc $20.76 USD +0.51
Durect Corp $2.44 USD +0.10
Isis Pharmaceuticals Inc $67.76 USD +0.59
View Industry Companies
 

Industry Analysis

ACOR

Industry Average

Valuation ACOR Industry Range
Price/Earnings 98.0x
Price/Sales 3.2x
Price/Book 2.5x
Price/Cash Flow 98.7x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACORDA THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.